Pioneering a powerful new approach to generate vaccines.

Developing RDFox, the world’s most powerful market-ready knowledge graph and semantic reasoner.

Exploitation of proprietary ‘Cell seq’ Technology platform

Maritime trade and transport simulation.

A broadcast personalisation engine to revolutionise audience experience.

Virtual Reality software to help treat people with severe paranoia by allowing them to face situations that they fear.

Ubiquitous wireless power and data using metamaterials.

EnzBond aims to change the current understanding of enzyme evolution process.

Proxisense specialise in advanced sensors, diagnostics and optimisation systems to prevent downtime & equipment failure. They improve performance & efficiency of complex rotating equipment.

Circadian Therapeutics identify and bring to market pharmaceutical and diagnostic platforms for the effective management of physiological and pathological conditions through their ability to modify the body's circadian rhythms.

Develop technologies that miniaturise fluid handling to accelerate drug discovery.

The OxSight ‘SmartSpecs’ help sight impaired and blind people to navigate independently, avoid collisions and see in the dark.

Researches, designs and will market diagnostic tests for the measurement of clinical bio markers that reduce healthcare costs and improve patient outcomes.

OxStem is a developer of cell programming therapies.

Oxford Nanoimaging’s microscope, the Nanoimager, is a single-molecule fluorescence microscope.
It is about 30 times smaller and significantly less expensive than current super-resolution microscopes and will be manufactured in the UK.

EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.

The development of cancer drugs that reprogram cancer cells to undergo the body's natural process of cell death.

DiffBlue is a world leader in automated test generation. Their products have been developed with industry partners over the last ten years and replace the manual process of writing tests.

The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer.

Specialise in applying state-of-the-art mass spectrometry platforms to characterising intact protein assemblies, often referred to as native mass spectrometry.